Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

New pact to develop radiopharmaceuticals

by Shi En Kim
April 1, 2023 | A version of this story appeared in Volume 101, Issue 11

 

Bicycle Therapeutics will work with Novartis to develop radioconjugates for cancer. Bicycle’s pipeline consists of double-looped, synthetic peptides conjugated to chemical payloads such as toxins. Bicycle will discover drug candidates for the pharma giant to commercialize. Under the terms of the agreement, Bicycle will receive $50 million up front and as much as $1.7 billion in milestone payments, plus royalties.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.